Tech Company Financing Transactions
EonArk Funding Round
EonArk, based in Shenzhen, secured $14 million in investment from Boyu Capital and Monolith Capital Partners.
Transaction Overview
Company Name
Announced On
7/21/2026
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Seed
Proceeds Purpose
The company plans to utilize the fresh capital to support research advancement and team expansion, specifically focusing on the development of its longevity virtual cell platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Shenzhen, Undisclosed
China
Shenzhen, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Overview
Rewriting the Engineering Limits of Longevity Intervention with AI, EonArk is reconstructing the R&D pathway for anti-aging drugs using cross-species data, Building the world's leading LONGEVITY FOUNDATION MODEL, Making aging go from unpredictable to computable and intervenable. We believe aging is not a fate to be passively endured, but a complex system that can be observed, modeled, and intervened upon. Starting from cross-species aging research, EonArk explores the future of healthy longevity through data, AI, and biotechnology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Si Zhao
Browse more venture capital transactions:
Prev: 7/20/2026: Raghu Vamsi Aerospace Group venture capital transaction
Next: 7/21/2026: Photon Queue venture capital transaction
Share this article
News on VC Transactions
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs